Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04408092 · ClinicalTrials.gov registry record · Early Phase 1
Study of the Effect of GM-CSF on Macrophages in Ependymoma
A Early Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT04408092 is a Early Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 6 participants.
The verdict
NCT04408092, a Early Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulation Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients with an ependymoma
Interventions
- DRUG Granulocyte Macrophage Colony Stimulation Factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-06-25 |
| Est. Completion | 2023-07-21 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04408092
The ClinicalTrials.gov registry entry for NCT04408092 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Granulocyte Macrophage Colony Stimulation Factor is the first listed.
NCT04408092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04408092 about?
NCT04408092 is a clinical study titled "Study of the Effect of GM-CSF on Macrophages in Ependymoma". This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulation Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients wi...
What is the current status of trial NCT04408092?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2013-06-25. Estimated completion is 2023-07-21.
What interventions are being tested in trial NCT04408092?
The interventions under investigation include: Granulocyte Macrophage Colony Stimulation Factor (DRUG).
Who is sponsoring clinical trial NCT04408092?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.